Priyanka Vakkalanka1, Brian C Lund2, Stephan Arndt3, William Field4, Mary Charlton5, Marcia M Ward6, Ryan M Carnahan5. 1. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa; Department of Emergency Medicine, University of Iowa Carver College of Medicine, University of Iowa Health Care, Iowa City, Iowa. Electronic address: priyanka-vakkalanka@uiowa.edu. 2. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa; Center for Comprehensive Access and Delivery Research and Evaluation, Iowa City Veterans Affairs Health Care System, Iowa City, Iowa. 3. Department of Biostatistics, University of Iowa College of Public Health, Iowa City, Iowa; Department of Psychiatry, University of Iowa Carver College of Medicine, University of Iowa Health Care, Iowa City, Iowa. 4. Department of Occupational and Environmental Health, University of Iowa College of Public Health, Iowa City, Iowa. 5. Department of Epidemiology, University of Iowa College of Public Health, Iowa City, Iowa. 6. Department of Health Management and Policy, University of Iowa College of Public Health, Iowa City, Iowa.
Abstract
INTRODUCTION: Veterans with opioid use disorder have an increased risk of suicide and overdose compared with the general population. Buprenorphine, a U.S. Food and Drug Administration-approved medication to treat opioid use disorder, has shown benefits, including decreased risk of illicit drug use and overdose. This study assesses the mortality outcomes with buprenorphine pharmacotherapy among Veterans up to 5 years from treatment initiation. METHODS: This was a retrospective cohort study of Veterans receiving buprenorphine (2008-2017) across any Veterans Health Administration facility. Buprenorphine pharmacotherapy was evaluated as a time-varying covariate. The primary outcome was death up to 5 years from treatment initiation by suicide and overdose combined; secondary outcomes included suicide, overdose, opioid-specific overdose, and all-cause death. Secondary analyses included evaluating the risk of mortality in recent discontinuation and effect modification by select characteristics. All analyses were conducted in 2020. RESULTS: Veterans who were not receiving buprenorphine were 4.33 (adjusted hazard ratio; 95% CI=3.60, 5.21) times more likely to die by suicide/overdose than those receiving buprenorphine pharmacotherapy on any given day, with similar protective associations with treatment across secondary outcomes. The risk of suicide/overdose was highest 8-14 days from treatment discontinuation (adjusted hazard ratio=6.54, 95% CI=4.32, 9.91) than in currently receiving buprenorphine pharmacotherapy. There was no evidence of effect modification by the selected covariates. CONCLUSIONS: Mortality risk was greater among Veterans who were not receiving buprenorphine pharmacotherapy than among those who were. Providers should consider whether buprenorphine pharmacotherapy, either intermittent or continuous, may provide health benefits for their patients and prevent mortality.
INTRODUCTION: Veterans with opioid use disorder have an increased risk of suicide and overdose compared with the general population. Buprenorphine, a U.S. Food and Drug Administration-approved medication to treat opioid use disorder, has shown benefits, including decreased risk of illicit drug use and overdose. This study assesses the mortality outcomes with buprenorphine pharmacotherapy among Veterans up to 5 years from treatment initiation. METHODS: This was a retrospective cohort study of Veterans receiving buprenorphine (2008-2017) across any Veterans Health Administration facility. Buprenorphine pharmacotherapy was evaluated as a time-varying covariate. The primary outcome was death up to 5 years from treatment initiation by suicide and overdose combined; secondary outcomes included suicide, overdose, opioid-specific overdose, and all-cause death. Secondary analyses included evaluating the risk of mortality in recent discontinuation and effect modification by select characteristics. All analyses were conducted in 2020. RESULTS: Veterans who were not receiving buprenorphine were 4.33 (adjusted hazard ratio; 95% CI=3.60, 5.21) times more likely to die by suicide/overdose than those receiving buprenorphine pharmacotherapy on any given day, with similar protective associations with treatment across secondary outcomes. The risk of suicide/overdose was highest 8-14 days from treatment discontinuation (adjusted hazard ratio=6.54, 95% CI=4.32, 9.91) than in currently receiving buprenorphine pharmacotherapy. There was no evidence of effect modification by the selected covariates. CONCLUSIONS: Mortality risk was greater among Veterans who were not receiving buprenorphine pharmacotherapy than among those who were. Providers should consider whether buprenorphine pharmacotherapy, either intermittent or continuous, may provide health benefits for their patients and prevent mortality.
Authors: Christine M Wilder; Shannon C Miller; Elizabeth Tiffany; Theresa Winhusen; Erin L Winstanley; Michael D Stein Journal: J Addict Dis Date: 2016
Authors: Jake R Morgan; Bruce R Schackman; Zoe M Weinstein; Alexander Y Walley; Benjamin P Linas Journal: Drug Alcohol Depend Date: 2019-05-03 Impact factor: 4.852
Authors: Rachel Peterson; Adi V Gundlapalli; Stephen Metraux; Marjorie E Carter; Miland Palmer; Andrew Redd; Matthew H Samore; Jamison D Fargo Journal: PLoS One Date: 2015-07-14 Impact factor: 3.240
Authors: Helen E Jack; Eric D Denisiuk; Brett A Collins; Dan Stephens; Kendra L Blalock; Jared W Klein; Elenore P Bhatraju; Joseph O Merrill; Kevin A Hallgren; Judith I Tsui Journal: Subst Abus Date: 2022-12 Impact factor: 3.984
Authors: Madeline C Frost; Julie E Richards; John R Blosnich; Eric J Hawkins; Judith I Tsui; E Jennifer Edelman; Emily C Williams Journal: Drug Alcohol Depend Date: 2022-06-03 Impact factor: 4.852